CAMBRIDGE, Mass., Oct. 3, 2018 /PRNewswire/ -- BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, announced today that Dr. Emile Nuwaysir, the Company's President and Chief Executive Officer, has been elected Vice Chairman of the Alliance for Regenerative Medicine (ARM), an international organization representing the cell and gene therapies community. Dr. Nuwaysir succeeds Matt Patterson, Chief Executive Officer of Audentes Therapeutics, who will complete his two-year term as Vice Chairman on Dec. 31, 2018 and assume the Chairman role.
"ARM is the preeminent international organization for the regenerative medicine and advanced therapies industry," said Dr. Nuwaysir. "As a direct result of ARM's past advocacy, these revolutionary therapies are developed more quickly, accelerating patient access to safe and effective products. I am honored by this appointment, as these advanced cell and gene therapies represent the next generation of medicine by addressing the underlying causes of disease. I look forward to helping further develop and implement ARM's strategy in regenerative medicine over the course of my term."
"We extend our congratulations to Dr. Nuwaysir for this notable appointment," said Jane Lambert, CEO of ARM. "BlueRock is a leading company and plays a critical role in the regenerative medicine industry, and Dr. Nuwaysir will be a valuable asset as ARM works to support the development of regenerative medicine products for patients."
Dr. Nuwaysir possesses deep knowledge of regenerative medicine and cell therapy, which he has utilized to cultivate innovative life science companies that are fueled by cutting-edge technologies. Dr. Nuwaysir has served in executive roles at Cellular Dynamics International (CDI) – A Fujifilm Company, Opsis Therapeutics Inc. and Roche NimbleGen. He holds a B.A. from the University of Delaware, and a Ph.D. in molecular toxicology with a focus in oncology from the University of Wisconsin at Madison.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
About BlueRock Therapeutics
BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock's Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock's culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.
David Schull or Maggie Beller
Russo Partners, LLC
SOURCE BlueRock Therapeutics, LP